Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19

• Status: Completed
• Trial end date: 2021-09-02
• Target enrollment: 0
• Participant gender: All

Summary

It is known that the pretreatment with exogenous interferon blocks SARS-CoV-2 infection, but intervention is much more effective if administered prior to infection. In this study the primary aim is to investigate 28-day regime of nasal interferon gama use in healthy participants for COVID-19 and other respiratory infections prevention.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: SPP Pharmaclon Ltd.
• Treatments: Interferon-gamma; Interferons

Criteria

Inclusion Criteria:

• Volunteers of both sexes over 18 years of age.

• Obtaining written informed consent.

• Ability and consent to participate in this research.

• Absence of symptoms of respiratory infection.

• A negative result of a PCR study for the presence of RNA SARS-CoV-2 according to biomaterial obtained by nasopharyngeal smear.

Exclusion Criteria:

• Any other concomitant diseases or conditions, which, in the opinion of the research doctor, may distort research results, restrict the rights of a volunteer or put him/her at greater risk.

• Contraindications to the use of the investigated medicinal product.

• Individual intolerance to the ingredients included in the composition of the investigational medicinal product.

• Pregnancy or breastfeeding.

• Doubtful result of a PCR test for the presence of RNA SARS-CoV-2 in the biomaterial obtained by nasopharyngeal smear.

• Participation in a clinical trial using study therapy within 30 days prior to enrollment in this study.

• Disagreement to follow in the research reliable contraceptive measures (abstinence; or a combination of 2 different methods: for example, barrier and spermicides, or barrier and intrauterine device, or barrier and hormonal, etc.) - for participants with saved reproductive potential.